GLPwatch
Trials (2036)
Page 22 of 34.
- Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
- Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?
- The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients
- Evaluation of Exenatide in Patients With Diabetic Neuropathy
- 16-week Flexible vs. 8-week Semaglutide Titration
- Liraglutide Treatment in Obese Infertile PCOS Women
- A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
- Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
- Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
- Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
- Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes
- A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
- Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity
- Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
- Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
- Research of Intensive Metabolic Intervention Before Pregnancy in PCOS
- Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
- DUTCH Weight Control in Atrial Fibrillation Study
- LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
- Clinical Outcomes of Exenatide Versus Basal Insulin
- The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers
- Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
- Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
- Real-life Evaluation of WEGOVY (Semaglutide) Treatment in Adults With Monogenic Obesity (ObGeSema)
- Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
- The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
- Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
- Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
- Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
- A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
- A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
- A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
- Impact of Semaglutide on Tobacco Use and Related Health Behaviors
- Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
- Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
- Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes
- Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
- Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
- Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
- A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
- Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
- SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
- GLP Analogs for Diabetes in Wolfram Syndrome Patients
- A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)
- Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying
- Metabolic Surgery for Atrial Fibrillation Elimination
- Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Semaglutide and Preoperative Residual Gastric Volumes
- Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
- Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
- A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)